GlassScriptPhysician profile
Shubham Adroja
NPI 1467016519
$1,592.16
in general payments reported to CMS, 2019-2025
15 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $393 · 2023: $322 · 2024: $713 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.68 |
| Education | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $324.55 | 2022-2023 | Livtencity, Alunbrig |
| Astellas Pharma US INC | $271.93 | 2022-2024 | Vyloy, Cresemba |
| Genzyme Corporation | $210.92 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $192.18 | 2024 | Ultomiris |
| Sobi, INC | $109.12 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $102.12 | 2025 | Datroway |
| Novartis Pharmaceuticals Corporation | $82.04 | 2024 | |
| Incyte Corporation | $75.31 | 2022-2024 | Jakafi |
| Rigel Pharmaceuticals, INC. | $61.06 | 2022 | |
| Adaptive Biotechnologies Corporation | $32.69 | 2025 | Clonoseq |
| Pfizer INC. | $28.93 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $27.50 | 2023 | Libtayo |
| Amgen INC. | $27.24 | 2022 | |
| Array Biopharma INC | $27.06 | 2023 | Braftovi, Lorbrena, Xalkori |
| Btg International INC. | $19.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shubham Adroja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.